BridgeBio Pharma BBIO Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating lease liabilities?
- BridgeBio Pharma (BBIO) reported operating lease liabilities of $14.22M in Q1 2026.
- How has BridgeBio Pharma's operating lease liabilities changed year-over-year?
- BridgeBio Pharma's operating lease liabilities increased by 189.2% year-over-year, from $4.92M to $14.22M.
- What is the long-term trend for BridgeBio Pharma's operating lease liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities has grown at a -23.6% compound annual growth rate (CAGR), from $14.68M to $3.81M.
- What does operating lease liabilities mean?
- The portion of rent and lease payments due after more than one year.
- How do you interpret operating lease liabilities?
- High levels indicate a long-term commitment to physical space, which is necessary for sustained R&D operations.
- How does operating lease liabilities compare across companies?
- These liabilities are typical for established biotech firms with dedicated laboratory and corporate headquarters.